// App-Quantinova.ai

EP632 : VENETOCLAX-OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION-BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY

Researchers

Presenter

  • Othman Al-Sawaf

Principal Investigators

  • Tong Lu

  • Michael Z Liao

  • Anesh Panchal

  • Sandra Robrecht

  • Travers Ching

  • Maneesh Tandon

  • Anna Fink

  • Eugen Tausch

  • Matthias Ritgen

  • Sebastian Bttcher

  • Karl Kreuzer

  • Su Kim

  • Dale Miles

  • Clemens Wendtner

  • Barbara Eichhorst

  • Stephan Stilgenbauer

  • Yanwen Jiang

  • Michael Hallek

  • Kirsten Fischer

Medical Centers

  • Genentech,Sunnyvale,United States

  • Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

  • Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany

  • AbbVie, N Chicago, United States

  • Genentech Inc., San Francisco, United States

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Department III of Internal Medicine, University Hospital Rostock, Rostock, Germany

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Adaptive Biotechnologies Corp,Seattle,United States

  • Genentech Inc., San Francisco, United States

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved